Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab for subclinical cardiovascular abnormalities in systemic lupus erythematosus
2021-001802-30Phase 4Terminated
- Sponsor
- Fraunhofer Institute for Translational Medicine and Pharmacology
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of belimumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Fraunhofer Institute for Translational Medicine and Pharmacology. Primary endpoint: Change in diffuse myocardial inflammation and myocardial blood flow at week 24. Started Sep 2021; status: terminated.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2021-001802-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001802-30.